



RMB'000 *RMB'000*
(U a d ed) *(U a d ed)*

Re e e	180,679	208,531
G f ⁽¹⁾	80,702	84,443
Ne ()/ f ⁽²⁾⁽⁴⁾	(566,992)	94,925
Ba c ()/ea g e ha e (RMB)	(3.874)	0.594

Ne :

- (1) The g f f he G f he Re g Pe d a ed RMB80.7 . Ad ed g f cac a ed a he g f f he Re g Pe d, e c d g he ac f he e e e f ha e-ba ed a a d a da a f de fabe a g be a e de fed ac .
- (2) The G ec ded a e f RMB567.0 d g he Re g Pe d. The ad ed e f (he ) cac a ed a he f f he Re g Pe d e c d g he ac f ce a e h ch a e c de ed a - ea g b he a age e , c d g () he e e a e e e f ha e-ba ed a a d f RMB0.4 a d he e-ffe ee be ef e e e f RMB2.0 ; () he ga he f e g e cha ge a d e e a fa a e cha ge f RMB5.7 a g f he c e f H g K g d a de a e d c e b e b d e d b he C a RMB, a d f e g e cha ge ga f RMB11.2 a a g f ca h a d ca h e ae ; () a a f de fabe a g be a e de fed ac f RMB15.3 ; () f a c a e e e he f a c a ab a a ed c f RMB4.8 ; () a e e a g be a e f RMB668.2 , a d he e e a f de fe ed c e a ab e ca ed b he a e c da ed a g be a e f RMB50.3 . F he ca c a f he Ad ed Ne P f , a ac f he ad ed e e e c de ed.
- (3) F he C e d g Pe d f P e Yea , he ad ed e f he C e d g Pe d f P e Yea d d a e c de a he effec f he f a c a c e he f a c a ab a a ed c f RMB1.0 he ad ed e f . If h a a e c de a , he ad ed e f a d he ad ed e f ag f he C e d g Pe d f P e Yea ha be a f , e ec f h ch he G d d a e a ad e he e e d f he da a d c ed he C e d g Pe d f P e Yea :



RMB'000 *RMB'000*
(U a d ed) *(U a d ed)*

Ad ed e f	56,474	51,767
Ad ed e f a g	31.3%	24.8%

The following table sets forth the historical changes in the carrying amount of the Group's available-for-sale financial assets, which are measured at fair value (the "fair value").

		RMB'000 (Audited)	RMB'000 (Audited)
Carrying amount at the beginning of the year	3	180,679 (99,977)	208,531 (124,088)
Additions		80,702 (29,507)	84,443 (33,722)
Net changes in fair value		(3,754)	
Disposals	7	(668,219)	
Other changes		3,492	515
	4	5,344	42,579
Fair value at the end of the year		(611,942)	93,815
Fair value at the beginning of the year		21,122	25,246
		(11,094)	(6,122)
Impairment losses	5	(601,914)	112,939
		34,922	(18,014)
Other changes		(566,992)	94,925
		(566,992)	94,925
Other changes		(535,403)	82,029
Net change		(31,589)	12,896
		(566,992)	94,925
Balance at the end of the year (RMB)	6	(3,874)	0.594
Balance at the beginning of the year (RMB)	6	(3,874)	0.005

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.

| | | RMB'000
(U a d ed) | RMB'000
(A d ed) |
|-----------------------------------|---|-----------------------|---------------------|
| P e , a a d e e | | 143,168 | 146,176 |
| R g h - f - e a e | | 40,328 | 42,011 |
| I a g b e a e | 7 | 2,222,222 | 2,905,829 |
| D e f e d c e a a e | | 2,054 | 1,413 |
| O h e e c e a b e , d e a d e a e | | 2,901 | 2,012 |
| A d e f a e a e d a | | 80,000 | 80,000 |
| | | <hr/> | <hr/> |

| | | 2019
RMB'000
(Unaudited) | 2018
RMB'000
(Audited) |
|-------------------|----|--------------------------------|------------------------------|
| Beginning | | 69,462 | 99,658 |
| Change | 10 | 1,284,486 | 1,693,430 |
| Lease | | 316 | 650 |
| Deferred lease | | 300,153 | 350,087 |
| Accumulated lease | | 175 | 362 |

The Company of China Limited (the Company) was incorporated in the Cayman Islands on February 21, 2014 and is a wholly owned subsidiary of the Company Limited (the Company Limited) (the Company Limited) of the Cayman Islands. The address of the Company is registered office PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.


The Company, together with its subsidiaries (collectively referred to as the Group), are engaged in the following business activities: (i) the provision of financial services; (ii) the provision of financial services; and (iii) the provision of financial services. The Company is a subsidiary of the Company Limited (the PRC).

The Company is a subsidiary of the Company Limited (the Company Limited), a subsidiary of the Company Limited (the Company Limited), a subsidiary of the Company Limited (the Company Limited).

The Company is a subsidiary of the Company Limited (the Company Limited) of the Cayman Islands. The Company is a subsidiary of the Company Limited (the Company Limited) of the Cayman Islands.

The Company is a subsidiary of the Company Limited (the Company Limited) of the Cayman Islands. The Company is a subsidiary of the Company Limited (the Company Limited) of the Cayman Islands.

The Company is a subsidiary of the Company Limited (the Company Limited) of the Cayman Islands. The Company is a subsidiary of the Company Limited (the Company Limited) of the Cayman Islands.



O e a g e g e a e e ed a a e c e h he e a e g ded he ch ef
e a g dec - a e (CODM). The CODM, h e b e f a ca g e ce a d a e g

| | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
|----------------------------|----------------|------------------|----------------|------------|------------------|------------------|
| Segment operating income | 98,301 | 108,181 | 2,948 | (899) | | 208,531 |
| Interest expense | | | (899) | 899 | | |
| Reconciliation | <u>98,301</u> | <u>108,181</u> | <u>2,049</u> | | | <u>208,531</u> |
| Transaction fees | | | | | | |
| Administrative | 46,419 | | 2,049 | | | 48,468 |
| Other | 51,882 | 108,181 | | | | 160,063 |
| | <u>98,301</u> | <u>108,181</u> | <u>2,049</u> | | | <u>208,531</u> |
| EBITDA | 1,079 | 90,213 | (578) | 479 | | 91,193 |
| Depreciation | (3,673) | (1,016) | (285) | | (542) | (5,516) |
| Amortization | (3,787) | (11,858) | (191) | | (46) | (15,882) |
| Finance (income) / expense | (851) | 124 | 4 | | (2,126) | (2,849) |
| Unaudited change | | | | | 45,993 | 45,993 |
| (Loss) / Profit before tax | <u>(7,232)</u> | <u>77,463</u> | <u>(1,050)</u> | <u>479</u> | <u>43,279</u> | <u>112,939</u> |
| Segment assets | 414,247 | 1,588,475 | 3,557 | | 851,665 | 2,857,944 |
| Goodwill | 301,995 | 1,306,506 | 9,266 | | | 1,617,767 |
| Total assets | <u>716,242</u> | <u>2,894,981</u> | <u>12,823</u> | | <u>851,665</u> | <u>4,475,711</u> |
| Total liabilities | <u>143,038</u> | <u>358,906</u> | <u>2,148</u> | | <u>2,202,078</u> | <u>2,706,170</u> |

Unaudited

| | RMB'000
(Unaudited) | RMB'000
(Unaudited) |
|------------------------------|------------------------|------------------------|
| Non-financial assets | 5,687 | 41,031 |
| Non-financial assets of FVPL | 781 | 3,196 |
| Other | (1,124) | (1,648) |
| | <u>5,344</u> | <u>42,579</u> |

Subsidiary accounted for 25% (15%) of the PRC consolidated revenue for the year ended June 30, 2019; 25% (15%) of the PRC consolidated revenue for the year ended June 30, 2020.

RMB'000
(Unaudited) RMB'000
(Unaudited)

Consolidated:

| | | |
|--------------------------|----------|--------|
| PRC consolidated revenue | 15,653 | 18,265 |
| Deferred revenue | (50,575) | (251) |
| | (34,922) | 18,014 |
| | (34,922) | 18,014 |

The Company accounted for the Capital Addition related to the acquisition of the Company's subsidiary, which is recorded as Capital Addition, net of cash paid.

Hong Kong subsidiary accounted for 16.5% (16.5%) of the year ended June 30, 2019; 16.5% of the year ended June 30, 2020. Net Hong Kong subsidiary income for the year ended June 30, 2020 and 2019.

The consolidated revenue of the Beijing Zhonghua Management Consulting Co., Ltd., Beijing Zhonghua Management Consulting Co., Ltd. and Hong Kong Ronghua accounted for 15% (15%) of the year ended June 30, 2019; 15% of the year ended June 30, 2020. The consolidated revenue of the subsidiary accounted for 25% (25%) of the year ended June 30, 2020.

The holding company of Beijing Shengde Holding Limited is a wholly-owned subsidiary of the PRC E-commerce Inc. The holding company of Beijing Shengde Holding Limited is a wholly-owned subsidiary of the PRC E-commerce Inc.

Net Profit of Holding Limited (Net Profit) has been determined based on the consolidated financial statements of Hong Kong Securities Administration Regulation Board, Weaglobe, consolidated financial statements of the holding company of Net Profit, effective from 2017 to 2019. After the acquisition, Net Profit of the holding company has been determined based on the consolidated financial statements of Weaglobe. As at December 31, 2019, Weaglobe has been determined based on the holding company's consolidated financial statements of 5%. Since January 1, 2020, the holding company has been determined based on the consolidated financial statements of 10%.

The holding company of the Net Profit subsidiary has been determined based on the consolidated financial statements of 10%.

Balance/equity changes attributable to the Company before deduction of taxes paid on dividends, 2020 and 2019.

| | 2020 | 2019 |
|---|----------------|----------------|
| | (U.S. dollars) | (U.S. dollars) |
| Balance/equity changes attributable to the Company before deduction of taxes paid on dividends (in thousands) | (535,403) | 82,029 |
| Weighted average basic shares outstanding (in thousands) | 138,194 | 138,121 |
| Balance/equity changes (in RMB) | <u>(3.874)</u> | <u>0.594</u> |

The Company had a dividend declared on December 30, 2020 and the corresponding dividend payment was made on January 30, 2021. The Company's board of directors declared a dividend on December 30, 2020, which was effective on January 30, 2021. The dividend was paid in cash.

| | 2020 | 2019 |
|---|----------------|----------------|
| | (U.S. dollars) | (U.S. dollars) |
| Balance/equity changes attributable to the Company before deduction of taxes paid on dividends (in thousands) | (535,403) | 82,029 |
| Change in cash and cash equivalents (in thousands) | 138,194 | 138,121 |
| Change in cash and cash equivalents (in RMB) | <u>(3.874)</u> | <u>0.005</u> |

| Ne b a e | | | | | |
|---------------------------|------------------|----------------|----------------|--------------|------------------|
| O e g a a a J a a 1, 2020 | 1,617,767 | 1,113,506 | 173,194 | 1,362 | 2,905,829 |
| A a | | (11,821) | (3,427) | (140) | (15,388) |
| I a e c h a g e | (467,083) | (201,136) | | | (668,219) |
| C g a a a J e 30, 2020 | <u>1,150,684</u> | <u>900,549</u> | <u>169,767</u> | <u>1,222</u> | <u>2,222,222</u> |

| Ne b a e | | | | | |
|---------------------------|------------------|------------------|----------------|--------------|------------------|
| O e g a a a J a a 1, 2019 | 1,617,767 | 1,137,153 | 180,047 | 1,572 | 2,936,539 |
| Add | | | | 178 | 178 |
| A a | | (11,823) | (3,427) | (160) | (15,410) |
| C g a a a J e 30, 2019 | <u>1,617,767</u> | <u>1,125,330</u> | <u>176,620</u> | <u>1,590</u> | <u>2,921,307</u> |

| | RMB'000
(U a d ed) | RMB'000
(A d ed) |
|---------------------------------|-----------------------|---------------------|
| T a d e e c e a b e | 35,106 | 31,332 |
| L e : f a e f a d e e c e a b e | (4,754) | (1,000) |
| T a d e e c e a b e e | <u>30,352</u> | <u>30,332</u> |

The carrying amount of the Group's trade receivables as at the end of the reporting period is RMB 35,106 thousand as at the end of the reporting period.

As at June 30, 2020 and December 31, 2019, the ageing analysis of trade receivables is as follows:

| | 2020
RMB'000
(Unaudited) | 2019
RMB'000
(Audited) |
|-------------------|--------------------------------|------------------------------|
| 1 - 90 days | 24,563 | 25,428 |
| 91 - 180 days | 1,153 | 1,658 |
| 181 days - 1 year | 5,234 | 2,947 |
| Over 1 year | 4,156 | 1,299 |
| | <u>35,106</u> | <u>31,332</u> |

The ageing analysis of trade receivables as at the end of the reporting period is as follows:

| | 2020
RMB'000
(Unaudited) | 2019
RMB'000
(Audited) |
|-------------------|--------------------------------|------------------------------|
| Within 90 days | 13,480 | 11,458 |
| 91 - 180 days | 2,464 | 971 |
| 181 days - 1 year | 301 | 372 |
| Over 1 year | 733 | 524 |
| | <u>16,978</u> | <u>13,325</u> |

The carrying amount of trade receivables as at the end of the reporting period is RMB 16,978 thousand as at the end of the reporting period.

The effect of the above items is as follows:

| | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
|---|----------------|----------------|----------------|------------------|
| As at December 31, 2020 | 392,174 | 577,039 | 724,217 | 1,693,430 |
| Decrease in fair value of financial assets | 2,318 | (7,633) | 120 | (5,195) |
| Change in fair value of financial assets | 10,696 | (6,141) | (9,878) | (5,323) |
| Aggregate decrease in fair value of financial assets (net of gains) | (1,416) | 2,163 | (22) | 725 |
| Aggregate decrease in fair value of financial assets (net of gains) as at December 30, 2020 | (515) | 4,707 | (86) | 4,106 |
| | <u>403,257</u> | <u>570,135</u> | <u>714,351</u> | <u>1,687,743</u> |
| As at December 31, 2019 | 430,241 | 643,615 | - | 1,073,856 |
| Increase in fair value of financial assets | - | - | 682,160 | 682,160 |
| Decrease in fair value of financial assets | 2,318 | (7,633) | 120 | (5,195) |
| Change in fair value of financial assets | (35,931) | (44,686) | 39,953 | (40,664) |
| Aggregate decrease in fair value of financial assets (net of gains) | (642) | 636 | - | (6) |
| Aggregate decrease in fair value of financial assets (net of gains) as at December 30, 2019 | (1,290) | 6,234 | (110) | 4,800,140 |

| | \ / / | Dece be 31, 2019 |
|----------------|-------|------------------|
| V a | / | 30% |
| T e e a (ea) | / , | 1.18 |
| R fee ae f e e | / , , | 1.87% |
| D de d e d | / / / | 0.00% |

A a J e 30, 2020, he fa a e f he c e be b d a a ae HKD619,010,000, e ae a ae RMB565,428,000, h ch a de e ed b a de e de a f e d a e .

The g f ca he a a de e a ed c e be b d ed A g 7, 2018 e e ed a be :

| | \ / / | Dece be 31, 2019 |
|----------------|-------|------------------|
| V a | / | 30% |
| T e e a (ea) | - / | 3.60 |
| R fee ae f e e | / , , | 1.58% |
| D de d e d | / / / | 0.00% |

A a J e 30, 2020, he fa a e f he c e be b d a a ae HKD782,138,000, e ae a ae RMB714,437,000, h ch a de e ed b a de e de a f e d a e .

The g f ca he a a de e a ed c e be b d ed Feb a 27, 2019 e e ed a be :

| | \ / / | Dece be 31, 2019 |
|----------------|-------|------------------|
| V a | / | 30% |
| T e e a (ea) | / , , | 4.16 |
| R fee ae f e e | / , | 1.53% |
| D de d e d | / / / | 0.00% |

P a a e f he ha eh de ' ee g f C H ghe Feb a 18, 2020, he d de d, c d g hh d g a , a g RMB5,355,000 a ha eh de a d RMB2,295,000 ha eh de a dec a ed. The d de d a ha eh de a d ha eh de had bee e ed Feb a 21, 2020.




In the first half of the year, according to the requirements of the National Health Commission's 2020 Work Key Points, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).

(1) In the first half of the year, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).

(2) In the first half of the year, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).

(3) In the first half of the year, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).


The National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).



I he f ha f f he ea , de he g da ce f e a a eg , he G f b ed
 he c ehe e e gh f e e ea a d ea ea h ca ea e
 a de a e e a ec acc da ce h he e ab hed e ec c e a f e e
 ec , c d g c d c g e c a d -de h a a f a e a ac
 a ge e de fed aga e f he ae e a g c d , c ca g
 h a d de a d g f a e h a he e d c be f c ed b he G ,
 c d c g e e f ch h a , e cha ge a d d c ab fea be
 f ce a ec h a ed be a aged b he G h ch he G d
 de c g e ce , a a g f c he I e e hea hca e d , e g he
 e e a f I e e dag a d ea e de , a d c ba g ec ha c b e
 e a d ff e hea hca e e ce .

The G c d ced e e e ga e a ec e a ea ch a Ta ,
 J a g , A h , Zhe a g , Y a , G a gd ga d Ch g g . Ba ed he de c de a
 f e e c e a a d a fe e ea ed c ca h he he a e a d a a f
 he he he ec e e e a aged a d had g h e a , f he e ga ce a
 ec ha bee aba d ed he ea e e a ec ha e bee e ec ed . I he ec d
 ha f f he ea , he G ac e f he e ec , c e c d a e
 a a e ' e ce de f e e a ec , e he de e e f e e g g
 b e e ch a ha ac a e ' e e e (自費藥房) , ed ca g (醫生集團) a d
 I e e h a (互聯網醫院) , e ac e h a ed ca g h g eg a
 f e ce e d c e a d g ea de e e e a c e a e h he a
 a c da e a de a d he G ' e ce- ha g h a e . Mea h e , he
 G e ha ce eg be ee ad a a d I e e hea hca e a d g ad a ea e he
 G ' d e fed e e e de de a a d f da f a che g a eg c g a
 f cce f ac , e a age e , ca e e a (收到、管好、上量) .

A e e , he be f bed he h a ed , a aged f ded b he G ()
 e a he a ea ha a a he e d f 2019 .



The G ad ed c ehe e ea e f he G H a ch a ea g a eg c
 g , e f c g c a de e e , d g a age e , g cad e ,
 g e e , a g a ac g d- h gh- e d a e , h ch fac a ed he
 c ed a d a d hea h de e e f each G H a .

(6) C a he e g f e ce a g G H a a d
g eade h a d e ce ha g f eg a ed ca ce e , a d ac e
ceed g h he c e ce e f de a ec d g he e acade c
bec fe ; a d

(7) Reg a g he a age e f he C a a d e g he g a age e ,
e ha c g effec e c ec h he ca a a e a d cea g he b a d f e ce
f he G he ca a a e , de a a g d f da f he f a c g
de e e f he G .

→

↑ ↓ ↖ ↗ ↘ ↙

D g he Re g Pe d, e e e a RMB180.7 , e e e g a dec ea e f
a ae 13.4% he c a ed h RMB208.5 f he C e d g Pe d f
Pe Yea , h ch a a a b abe a dec ea e a age e e ce fee de ed
f Sha gha Ya g H a * (上海楊思醫院) () a d Zhe a g J h a
G a gf Oc g ca H a * (浙江金華廣福腫瘤醫院) () a d a dec ea e
he a f e e e f he f ge e a h a e ce b Ja de H a f
T ad a Ch e e Med c e C ., L d.* (建德中醫院有限公司) () d d a
a e .

O e e e f he h a a age e e ce eg e c ded e e e f he
f h a a age e e ce Ya g H a , C U H a * (慈溪協和
醫院) () a d J h a H a . D g he Re g Pe d, he e e e f h
eg e a RMB101.0 , e e e g a dec ea e f 6.6% he c a ed h RMB108.2
f he C e d g Pe d f Pe Yea . The dec ea e e e e a a
a b abe he ac f COVID-19 a de c, h ch ca ed a dec ea e he a age e
e ce fee ec g ed f d g e ce Ya g H a a d J h a H a .

D g he Re g Pe d, e e e f he ge e a h a e ce eg e dec ea ed
b a ae 19.1% RMB79.6 f RMB98.3 he C e d g Pe d
f Pe Yea . Re e e f h eg e f he Re g Pe d dec ea ed a d e
a dec ea e he a f e e e f he f ge e a h a e ce b Ja de
H a d d a a e , h ch a he e f he dec ea e he be f - a e
a d - a e f Ja de H a f he Re g Pe d a affec ed b he COVID-19
a de c.

O ad ed g f a RMB96.4 f he Re g Pe d, e c d g he ac
f e e e f ha e-ba ed a a d a da a f de f abe a g be a e de fed
ac , e e e g a dec ea e f a ae 6.1% he c a ed h RMB102.6
f he C e d g Pe d f Pe Yea . Th a a a b abe he ac
f COVID-19 a de c, h ch ca ed a dec ea e he a age e e ce fee ec g ed f
d g e ce Ya g H a a d J h a H a .

We ec ded ad ed ad a e e e e f RMB27.5 f he Re g Pe d,
e c d g he ac f he e-ffe ee be ef e e e , e e e g a dec ea e f
14.1% he c a ed h RMB32.0 f he C e d g Pe d f Pe Yea ,
h ch a a d e a dec ea e fe a e ce fee f he Re g Pe d he
c a ed h he C e d g Pe d f Pe Yea .

We recorded additional expenses of RMB68.3 for the Reporting Period, a decrease of RMB4.4 for RMB72.7 for the Consolidated Reporting Period. The decrease in the accounts receivable due to COVID-19, which caused a decrease in the age of receivables, and the decrease in the accounts receivable.

We recorded additional expenses of RMB3.6 for the Reporting Period, a decrease of RMB6.5 for the Consolidated Reporting Period. The decrease in the accounts receivable due to COVID-19, which caused a decrease in the age of receivables, and the decrease in the accounts receivable. The decrease in the accounts receivable due to COVID-19, which caused a decrease in the age of receivables, and the decrease in the accounts receivable.

For the Reporting Period, the net profit of RMB56.5, a decrease of 9.1% for the Consolidated Reporting Period. The decrease in the net profit for the Reporting Period is due to the decrease in the net profit for the Reporting Period. The decrease in the net profit for the Reporting Period is due to the decrease in the net profit for the Reporting Period.



As of December 31, 2020, the total assets of RMB1,249.4 (December 31, 2019: RMB1,817.8). As of December 31, 2020, the total liabilities of RMB1,339.1 (December 31, 2019: RMB1,277.5) and the total equity of RMB925.9 (December 31, 2019: RMB492.9). As of December 31, 2020, the total number of shares is 1.45 billion, an increase of 2.59 billion from December 31, 2019.

Other receivables of RMB61.6 for the Reporting Period, a decrease of RMB1,277.5 from December 31, 2019 (RMB1,339.1). As of December 31, 2020, the total assets of RMB1,249.4 (December 31, 2019: RMB1,817.8) and the total liabilities of RMB1,339.1 (December 31, 2019: RMB1,277.5) and the total equity of RMB925.9 (December 31, 2019: RMB492.9).

Other receivables of RMB61.6 for the Reporting Period, a decrease of RMB1,277.5 from December 31, 2019 (RMB1,339.1). As of December 31, 2020, the total assets of RMB1,249.4 (December 31, 2019: RMB1,817.8) and the total liabilities of RMB1,339.1 (December 31, 2019: RMB1,277.5) and the total equity of RMB925.9 (December 31, 2019: RMB492.9).

1. The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2020 and has approved the financial statements.

The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2020 and has approved the financial statements.


The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2020 and has approved the financial statements.

The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2020 and has approved the financial statements.

Paragraph A.2.1 of the CG Code has been amended to read as follows: The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2020 and has approved the financial statements.



Th a ce e b hed he eb e f he H g K g E cha ge a d C ea g
 L ed (.h e e .h) a d he C a (.hcc hea hca e.c). The e e f
 he C a f he Re g Pe d be d a ched he ha eh de f he C a a d
 ade a a ab e f e g he ab e eb e d ec e.

B de f he B a d

 Cha a

Be g, Ch a, A g 28, 2020

A a he da e f h a ce e , he D ec f he C a a e M . SU Zh a g a d M .
 LU We be g he e ec e D ec ; M . CHEN Sh a , M . SHI We g , M . LIU L a d
 M . WANG Na be g he -e ec e D ec ; a d M . DANG J e , M . SHI L e a d
 M . ZHOU X a g a g be g he de e de -e ec e D ec .

* F de fca e